Related Experiment Video

Updated: Jan 2, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.3K

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma

Julie Delyon1,2, Céleste Lebbe1,2, Nicolas Dumaz3

  • 1Université de Paris, INSERM U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI).

Current Opinion in Oncology
|December 14, 2019
PubMed
Abstract

Insights

Targeted therapies for BRAF wild-type melanoma, including NRAS-mutated and KIT-altered types, are under development. Current MEK and KIT inhibitors show disappointing results, but combined strategies may offer future benefits.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Melanoma treatment has advanced significantly with immune checkpoint inhibitors and targeted therapies for BRAF-mutated cases.
  • Patients with BRAF wild-type melanoma lack effective targeted treatment options.
  • NRAS-mutated and KIT-altered melanomas represent distinct molecular subtypes requiring novel therapeutic approaches.

Purpose of the Study:

  • To review the clinical development of targeted therapies beyond BRAF inhibitors for NRAS-mutated and KIT-altered melanoma.
  • To assess the current status and future potential of targeted treatments for these melanoma subtypes.

Main Methods:

  • Review of current clinical trials and research on targeted therapies for NRAS-mutated and KIT-altered melanoma.
  • Analysis of therapeutic strategies including MEK inhibitors, KIT inhibitors, and combination therapies.

Main Results:

  • Targeted therapies for NRAS-mutated melanoma involve MEK inhibitors, often in combination with other agents (MAPK, PI3K, CDK4/6 inhibitors).
  • KIT-inhibitor therapies (imatinib, nilotinib) are being investigated for KIT-altered melanoma.
  • Current results for both NRAS-mutated and KIT-altered melanoma targeted therapies are generally disappointing compared to BRAF/MEK inhibitors in BRAF-mutated melanoma.

Conclusions:

  • Targeted therapies for NRAS-mutated and KIT-altered melanoma are still in development.
  • Combined therapeutic strategies are anticipated to be crucial for improving outcomes in these patient groups.
  • Further research and clinical trials are needed to optimize targeted treatments for BRAF wild-type melanoma.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.4K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K